Total Funding
47
46
Total FundingGrant raised
Growth Score
-7 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
127038
At SIGA, we specialize in developing therapeutic solutions for some of the most lethal pathogens – smallpox.
- Robin Abrams: Chief Administrative Officer and General CounselPast Role: Lexy, Director
Susan K Burgess: President
About the Company
SIGA is a pharmaceutical company specializing in the development of pharmaceutical solutions for some of the most lethal pathogens – variola (smallpox), Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm
dreaded viral diseases and create robust, modern biodefense countermeasures.
